Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent PlasmaHyung Park, Eva Petkova, Elliott M. Antman et al.|JAMA Network Open|2022Cited by 66
Early administration of <scp>COVID</scp>‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacyArtur Belov, Peter Marks, Anne F. Eder et al.|American Journal of Hematology|2022Cited by 21